Ingram JR, Porter M, Chovatiya R, Giamarellos-Bourboulis EJ, Bechara FG, Fujita H, Gulliver W, Muller E, Bari M, Rolleri R, Byerly R, Kirby JS. Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II. J of Skin [Internet]. 2024Mar.18 [cited 2024Jul.22];8(2):s396. Available from: https://jofskin.org/index.php/skin/article/view/2671